Subasumstat + Rituximab Shown to Be Tolerable in Subsets of non-Hodgkin Lymphoma Patients
![Subasumstat + Rituximab Shown to Be Tolerable in Subsets of non-Hodgkin Lymphoma Patients](https://d3wo5wojvuv7l.cloudfront.net/t_square_limited_480/images.spreaker.com/original/c3b6743d858ba52363857de0977be96e.jpg)
Sign up for free
Listen to this episode and many more. Enjoy the best podcasts on Spreaker!
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
Karuppiah Kannan, Senior Director - Global Program Leader at Takeda Pharmaceuticals, discusses early results of a phase 1/2 study evaluating subasumstat (TAK-981) in combination with rituximab in multiple subsets of...
show moreSubasumstat is an investigational, first-in-class small-molecule inhibitor of SUMOylation, which mediates cell cycle progression. In preclinical trials, subasumstat was shown to add synergistic benefit when combined with rituximab in non-Hodgkin lymphoma models.
Information
Author | Peter Ciszewski, CheckRare |
Organization | CheckRare |
Website | - |
Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company